FDA Rejects Novartis Biosimilar App for Amgen Neulasta

The U.S. FDA has declined to approve Novartis' application for a biosimilar copy of Amgen's blockbuster, Neulasta.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news